HCA
NMTR

Hillview Capital Advisors’s 9 Meters Biopharma NMTR Stock Holding History

Hillview Capital Advisors’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$23K Hold
981
– – 0.12% 6
2019
Q1 		$38K Hold
981
– – 0.2% 6
2018
Q4 		$45K Hold
981
– – 0.27% 4
2018
Q3 		$134K Buy
+981
New +$169K 0.52% 5

Other funds holding NMTR

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Hillview Capital Advisors's NMTR Position: Q2 2019 in Review

Hillview Capital Advisors held its 9 Meters Biopharma (NMTR) position steady in Q2 2019 at 981 shares worth $23K. The position accounts for 0.12% of the portfolio, ranked #6.

Hillview Capital Advisors first reported a position in NMTR in Q3 2018 and has held it in 4 quarters since. The position peaked at $134K in Q3 2018. 30 funds tracked by Wall St. Rank hold NMTR as of Q2 2019.

  • Hillview Capital Advisors held 981 shares of 9 Meters Biopharma worth $23K as of Q2 2019.
  • Hillview Capital Advisors left its 9 Meters Biopharma share count unchanged in Q2 2019.
  • 9 Meters Biopharma made up 0.12% of Hillview Capital Advisors's portfolio in Q2 2019, its #6 holding.
  • Hillview Capital Advisors first reported a position in 9 Meters Biopharma in Q3 2018 and has held it in 4 quarters since.
  • Hillview Capital Advisors's 9 Meters Biopharma position peaked at $134K in Q3 2018.
  • 30 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2019.

Based on Hillview Capital Advisors's 13F filing for Q2 2019, filed 1 Aug 2019.